A study found that 89% of Royal College of Physicians members believe that more complete reporting of clinical trial data will result in better drugs and patient care, but just 27% say release of full data should be tied to marketing approval. One in 10 respondents said greater dissemination of study findings will hurt manufacturers' commercial interests. "The world has changed. Society now demands greater transparency in clinical trials," said Dr. Keith Bragman of the Royal College's Faculty of Pharmaceutical Medicine.

Related Summaries